Literature DB >> 3144240

An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium.

P S Imperia1, H M Lazarus, E C Dunkel, D Pavan-Langston, P A Geary, J H Lass.   

Abstract

Using an in vitro system we measured the corneal epithelial cytotoxicity and the antiviral activity of the antiviral agents idoxuridine (IDU), trifluridine (TFT), ethyldeoxyuridine (EDU), and (E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU). Confluent rabbit corneal epithelial cell cultures were established, and the antiviral agents were added for 5, 30, or 60 min at a range of concentrations including that used clinically (IDU 0.1%, TFT 1.0%, BVDU 0.1%, EDU 2.0%). Twelve hour [3H]thymidine incorporation then was measured and expressed as % inhibition of control cultures. In separate experiments confluent corneal epithelial cell monolayers were inoculated with 10(4) plaque forming units (PFU) of HSV type 1 (McKrae strain) for 1 h, and IDU 0.1%, TFT 1.0%, and BVDU 0.1% were added to the culture for determination of PFU inhibition. Significant dose-, but not time-dependent, toxicity was observed at the clinical concentrations of IDU, TFT, and EDU. Toxicity was absent for BVDU. TFT and IDU were the most toxic, and EDU was of intermediate toxicity. IDU, TFT, and BVDU showed significant antiviral activity in this corneal epithelial cell culture system (TFT greater than BVDU greater than IDU). The results of this in vitro study paralleled the findings of previous in vivo corneal epithelial toxicity studies of IDU, TFT, and BVDU. Our data, however, suggest that EDU has a potential for clinical toxicity and further studies are recommended. Our model may be useful in the future toxicologic study of new antiviral agents.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144240     DOI: 10.1016/0166-3542(88)90057-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits.

Authors:  Partha S Bhattacharjee; Donna M Neumann; James M Hill
Journal:  Curr Eye Res       Date:  2009-02       Impact factor: 2.424

Review 2.  Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease.

Authors:  D Pavan-Langston
Journal:  Trans Am Ophthalmol Soc       Date:  1990

3.  Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea.

Authors:  Soumyajit Majumdar; Giridhar S Tirucherai; Dhananjay Pal; Ashim K Mitra
Journal:  AAPS PharmSci       Date:  2003

4.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Authors:  Gilbert G Jose; Inna V Larsen; Joshua Gauger; Erica Carballo; Rebecca Stern; Rachel Brummel; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

5.  An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Authors:  Paul J Park; Thessicar E Antoine; Asim V Farooq; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

6.  Extended Release of an Anti-Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal Herpes Simplex Virus-1 Infection.

Authors:  Dinesh Jaishankar; Jason S Buhrman; Tibor Valyi-Nagy; Richard A Gemeinhart; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-01-01       Impact factor: 4.799

7.  Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.

Authors:  Neel Thakkar; Dinesh Jaishankar; Alex Agelidis; Tejabhiram Yadavalli; Kyle Mangano; Shrey Patel; Sati Zeynep Tekin; Deepak Shukla
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.